DK2128625T3 - Bestemmelse af neutrofil gelatinase-associeret lipocalin (NGAL) som diagnostisk markør for nyrelidelser - Google Patents
Bestemmelse af neutrofil gelatinase-associeret lipocalin (NGAL) som diagnostisk markør for nyrelidelser Download PDFInfo
- Publication number
- DK2128625T3 DK2128625T3 DK09154624.2T DK09154624T DK2128625T3 DK 2128625 T3 DK2128625 T3 DK 2128625T3 DK 09154624 T DK09154624 T DK 09154624T DK 2128625 T3 DK2128625 T3 DK 2128625T3
- Authority
- DK
- Denmark
- Prior art keywords
- ngal
- renal
- human
- urine
- urinary
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (8)
1. Metode til at bestemme sandsynligheden for en nyrelidelse, som er valgt blandt akut nyresvigt, akut tubulær nekrose og akut tubulo-interstitiel nefropati, i et menneske, hvor metoden skelner mellem en nyrelidelse og en tilstand, som ikke påvirker nyren, hvilken metode omfatter trinnene: i) bestemmelse af koncentrationen af human neutrofil gelatinase-associeret lipocalin (NGAL) i en prøve af urin, serum eller plasma fra mennesket, ii) sammenligning af førnævnte koncentration med en forudbestemt grænseværdi på mellem 250 ng/mL og 525 ng/mL, der er valgt for at udelukke lavere koncentrationer af NGAL associeret med tilstande, der ikke påvirker nyren, hvor en koncentration over grænseværdien er indikation på sandsynligheden for nyrelidelsen.
2. Metode ifølge krav 1, hvor den tilstand, som ikke påvirker nyren, er en inflammatorisk lidelse eller infektiøse lidelser eller en cancerlidelse, og grænseværdien vælges for at udelukke lavere koncentrationer af NGAL associeret med inflammatoriske lidelser eller infektiøse lidelser eller cancerlidelser.
3. Metode ifølge et hvilket som helst af kravene 1-2, som omfatter det yderligere trin, at trin i) og ii) gentages én eller flere gange.
4. Metode ifølge et hvilket som helst af kravene 1-3, som omfatter det yderligere trin, at trin i) og ii) gentages inden for 24 timer, fx inden for 12 timer, såsom inden for 6 timer, fx inden for 3 timer.
5. Metode ifølge et hvilket som helst af kravene 1-4, som omfatter det yderligere trin, at trin i) og ii) gentages, efter at en behandling af nyrelidelsen er blevet igangsat eller fuldført.
6. Metode ifølge et hvilket som helst af kravene 1-5, hvor nyrelidelsen er en post-iskæmisk nyreskade.
7. Metode ifølge et hvilket som helst af kravene 1-6, hvor nyrelidelsen forårsages af et nefrotoksisk middel.
8. Metode ifølge et hvilket som helst af kravene 1-7, hvor NGAL måles ved hjælp af et molekyle, som binder specifikt til NGAL.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63750304P | 2004-12-20 | 2004-12-20 | |
US71930705P | 2005-09-21 | 2005-09-21 | |
EP05820913A EP1831699B1 (en) | 2004-12-20 | 2005-12-20 | Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2128625T3 true DK2128625T3 (da) | 2017-05-01 |
Family
ID=36011033
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09154624.2T DK2128625T3 (da) | 2004-12-20 | 2005-12-20 | Bestemmelse af neutrofil gelatinase-associeret lipocalin (NGAL) som diagnostisk markør for nyrelidelser |
DK05820913.1T DK1831699T3 (da) | 2004-12-20 | 2005-12-20 | Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme |
DK18195687.1T DK3489689T3 (da) | 2004-12-20 | 2005-12-20 | Bestemmelse af neutrofil gelatinase-associeret lipocalin (NGAL) som diagnostisk markør for nyresygdomme |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05820913.1T DK1831699T3 (da) | 2004-12-20 | 2005-12-20 | Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme |
DK18195687.1T DK3489689T3 (da) | 2004-12-20 | 2005-12-20 | Bestemmelse af neutrofil gelatinase-associeret lipocalin (NGAL) som diagnostisk markør for nyresygdomme |
Country Status (18)
Country | Link |
---|---|
US (3) | US20090170143A1 (da) |
EP (4) | EP1831699B1 (da) |
JP (1) | JP4741603B2 (da) |
KR (1) | KR100971305B1 (da) |
CN (1) | CN101163971B (da) |
AT (1) | ATE448484T1 (da) |
AU (1) | AU2005318689B2 (da) |
CA (1) | CA2591113C (da) |
DE (1) | DE602005013288D1 (da) |
DK (3) | DK2128625T3 (da) |
ES (4) | ES2703434T3 (da) |
HK (1) | HK1105454A1 (da) |
IL (1) | IL183872A (da) |
NZ (1) | NZ555926A (da) |
PL (2) | PL3489689T3 (da) |
SI (1) | SI1831699T1 (da) |
WO (1) | WO2006066587A1 (da) |
ZA (1) | ZA200705776B (da) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1616184T4 (da) * | 2003-03-27 | 2018-08-13 | Childrens Hospital Med Ct | Fremgangsmåde og kit til at påvise tidlig begyndelse af renal tubulær cellebeskadigelse |
US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
EP2035835B1 (en) * | 2006-05-30 | 2011-12-28 | Antibodyshop A/S | Methods for rapid assessment of severity of a trauma |
JP2010500535A (ja) * | 2006-08-07 | 2010-01-07 | アンチボディショップ・アクティーゼルスカブ | 重大な腎損傷を除外するための診断検査 |
EP2500723B1 (en) | 2006-11-14 | 2015-07-08 | Alere San Diego, Inc. | Methods for monitoring and risk prediction in cardiorenal syndrome |
WO2008061149A2 (en) * | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
US8101366B2 (en) * | 2006-12-20 | 2012-01-24 | Antibodyshop A/S | Assessment of patients with sepsis to determine a requirement for therapeutic intervention with an anti-inflammatory and/or anticoagulatory agent |
EP2126562B1 (en) * | 2007-02-23 | 2014-12-31 | Physicians Choice Laboratory Services, LLC | Clinical intervention directed diagnostic methods |
EP2137538B1 (en) | 2007-03-21 | 2014-04-09 | Bioporto Diagnostics A/s | Diagnostic test for renal injury |
US20090123946A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
WO2009059259A2 (en) * | 2007-10-31 | 2009-05-07 | Children's Hospital Medical Center | Detection of worsening renal disease in subjects with systemic lupus erythematosus |
EP2215481B2 (en) * | 2007-11-15 | 2017-01-18 | Bioporto Diagnostics A/S | Diagnostic use of individual molecular forms of a biomarker |
EP2257813A4 (en) * | 2008-03-12 | 2011-11-02 | Univ Columbia | NGAL WITH HIGH MOLECULAR WEIGHT AS BIOMARKER FOR CHRONIC KIDNEY DISEASE |
US7977110B2 (en) | 2008-06-02 | 2011-07-12 | Children's Hospital Medical Center | Method for distinguishing between kidney dysfunctions |
EP2324355B1 (en) | 2008-08-28 | 2014-01-22 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US20100105150A1 (en) * | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
WO2010054025A1 (en) | 2008-11-05 | 2010-05-14 | Abbott Laboratories | Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use |
AU2009318813B2 (en) * | 2008-11-21 | 2016-11-24 | Future Medical Diagnostics Co., Ltd | Methods, devices and kits for detecting or monitoring acute kidney injury |
US20100233740A1 (en) * | 2009-02-12 | 2010-09-16 | Jonathan Barasch | Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis |
US20100233739A1 (en) * | 2009-02-12 | 2010-09-16 | Jonathan Barasch | Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction |
ES2350078B1 (es) * | 2009-05-19 | 2011-11-15 | Consejo Superior De Investigaciones Científicas (Csic) | Celula del smf modificada geneticamente para sobreexpresar ngal y su uso como medicamento |
US20120214177A1 (en) * | 2009-06-17 | 2012-08-23 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for diagnosis of urosepsis and urinary tract infection |
EP2462443A4 (en) * | 2009-08-07 | 2013-01-30 | Rules Based Medicine Inc | METHODS AND DEVICES FOR DETECTING GLOMERULONEPHRITH AND ASSOCIATED DISORDERS |
CA2772336A1 (en) * | 2009-08-28 | 2011-03-03 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2011053832A1 (en) * | 2009-10-29 | 2011-05-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose sepsis in very low birth weight infants |
US20110195903A1 (en) * | 2009-12-15 | 2011-08-11 | Adra Chaker N | Methods and compositions for detecting recessive familial fsgs and uses thereof |
CN102072960A (zh) * | 2010-03-29 | 2011-05-25 | 武汉生之源生物科技有限公司 | 一种样本中中性粒细胞明胶酶相关脂质运载蛋白的检测方法 |
WO2011149962A1 (en) | 2010-05-24 | 2011-12-01 | The Trustees Of Columbia University In The City Of New York | Mutant ngal proteins and uses thereof |
US20130316370A1 (en) * | 2010-10-07 | 2013-11-28 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
CN102253217B (zh) * | 2011-04-07 | 2013-08-07 | 武汉生之源生物科技有限公司 | 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
TW201250248A (en) * | 2011-04-25 | 2012-12-16 | Kyowa Medex Co Ltd | Prognostication method of renal failure |
NL2007112C2 (en) | 2011-07-14 | 2013-01-15 | Brainlabs B V | Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness. |
US20130062516A1 (en) * | 2011-09-09 | 2013-03-14 | Hsien-Shou Kuo | Diganosis of a renal disease by oxygen and hydrogen isotopes in a biological sample |
GB2519208A (en) * | 2012-01-11 | 2015-04-15 | Craig Venter Inst J | Metaproteomic method for diagnosis of bacteriuria, urogenital tract and kidney infections from urinary pellet samples |
CN102662064A (zh) * | 2012-04-26 | 2012-09-12 | 苏州照康生物技术有限公司 | 检测中性粒细胞明胶酶相关脂质运载蛋白的免疫比浊试剂盒及其制备方法 |
EP2925337B1 (en) | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
CN203441604U (zh) | 2013-02-15 | 2014-02-19 | 通用电气公司 | 用于降低燃气涡轮系统中的背压的系统 |
US9651547B2 (en) | 2013-03-14 | 2017-05-16 | Abbott Point Of Care Inc. | Electrochemical methods and devices for amending urine samples for immunosensor detection |
US9488663B2 (en) | 2013-03-14 | 2016-11-08 | Abbott Point Of Care Inc. | Electrochemical methods and devices for amending urine samples for immunosensor detection |
PL2968443T3 (pl) | 2013-03-15 | 2022-02-07 | Protagonist Therapeutics, Inc. | Analogi hepcydyny i ich zastosowania |
KR101590622B1 (ko) | 2013-10-24 | 2016-02-01 | (주)메디컬그룹베스티안 | 화상 중증도 판단 방법 |
KR20230036156A (ko) | 2014-05-16 | 2023-03-14 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | α4β7 인테그린 티오에테르 펩티드 길항제 |
RU2736637C9 (ru) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
US11270782B2 (en) | 2014-11-19 | 2022-03-08 | Koninklijke Philips N.V. | Diagnostic method employing HNL |
CN104502596A (zh) * | 2014-12-23 | 2015-04-08 | 温州医科大学 | 一种慢性肾病诊断试剂盒 |
KR101657881B1 (ko) * | 2015-03-16 | 2016-09-19 | 대구한의대학교산학협력단 | 타깃 바이오마커에 고특이적이며 고선택적 결합이 가능한 펩타이드 프로브 및 그를 이용한 급성 및 만성 신장질환 조기진단용 바이오칩 |
EP3334498B1 (en) | 2015-08-12 | 2023-06-07 | The Trustees of Columbia University in the City of New York | Methods of treating volume depletion and kidney injury |
EP3184116B1 (en) | 2015-12-23 | 2020-09-16 | National Taiwan Normal University | Neutrophil gelatinase-associated lipocalin for use in prevention or treatment of polycystic kidney disease |
TWI581802B (zh) | 2015-12-23 | 2017-05-11 | 國立臺灣師範大學 | 嗜中性白血球膠原蛋白質酶相關疏水性蛋白質之製藥用途 |
CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
WO2018089693A2 (en) * | 2016-11-09 | 2018-05-17 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
KR102094608B1 (ko) * | 2018-08-08 | 2020-04-23 | 고려대학교 산학협력단 | 혈액암의 분류 및 예후 판단에 필요한 정보를 제공하는 방법 |
CN109781990A (zh) * | 2018-12-25 | 2019-05-21 | 无锡市人民医院 | 一种β-痕迹蛋白检测试剂盒及制备方法 |
KR102293024B1 (ko) * | 2020-02-07 | 2021-08-24 | 고려대학교 산학협력단 | 혈액 종양 질환 특이적 바이오마커 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3635091A (en) * | 1970-08-31 | 1972-01-18 | Frederick D Linzer | Midstream urine specimen and fractional fluid collectors |
IT1074038B (it) * | 1976-08-05 | 1985-04-17 | Simes | Esteri della epinina |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4357343A (en) * | 1981-06-26 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Nutritional composition for management of renal failure |
US4659678A (en) * | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
US4640909A (en) * | 1985-05-07 | 1987-02-03 | J. T. Baker Chemical Company | Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction |
US5939272A (en) * | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
US5200319A (en) * | 1989-10-27 | 1993-04-06 | The General Hospital Corporation | Diagnosis of glomerulonephritis |
JP2912413B2 (ja) * | 1990-03-28 | 1999-06-28 | 東亜医用電子株式会社 | 粒度分布作成方法 |
US5405832A (en) * | 1991-11-27 | 1995-04-11 | Immtech International Inc. | Method of treating non-streptococcal bacterial infections |
US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
SE9401351D0 (sv) | 1994-04-21 | 1994-04-21 | Venge | A method for diagnosis |
US5552313A (en) * | 1994-11-21 | 1996-09-03 | Kansas University | DNA encoding mouse phosphotriesterase-related protein |
US5750345A (en) * | 1995-10-31 | 1998-05-12 | Evanston Hospital Corporation | Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders |
US5627034A (en) * | 1995-12-05 | 1997-05-06 | Wisconsin Alumni Research Foundation | Assay for carcinoma proliferative status by measuring NGAL expression level |
PT907735E (pt) * | 1996-05-24 | 2006-06-30 | Biogen Idec Inc | Moduladores da regeneracao de tecidos |
WO1999007740A2 (en) * | 1997-08-06 | 1999-02-18 | Zymogenetics, Inc. | Lipocalin homologs |
US6309888B1 (en) * | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
AUPP784398A0 (en) * | 1998-12-21 | 1999-01-21 | Monash University | Kidney disease detection and treatment |
AU5330200A (en) * | 1999-06-18 | 2001-01-09 | Michigan State University | Method and apparatus for the detection of volatile products in a sample |
US6762032B1 (en) * | 1999-08-23 | 2004-07-13 | Biocrystal, Ltd. | Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response |
WO2002029409A2 (en) * | 2000-10-03 | 2002-04-11 | Rowett Research Institute | Method of assaying pyrrole-containing biological compounds |
US6564385B2 (en) * | 2000-10-06 | 2003-05-20 | Mccarthy Daniel J. | Handling device |
AU2002211697B2 (en) * | 2000-10-13 | 2005-12-15 | Children's Medical Center Corporation | Non-invasive enzyme screen for tissue remodelling-associated conditions |
FI20010019A (fi) * | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen diagnostisoimiseksi |
US20040203083A1 (en) * | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
DE10120614A1 (de) | 2001-04-26 | 2002-10-31 | Sms Demag Ag | Kühlplatte |
EP1666881B1 (en) * | 2001-05-04 | 2010-02-17 | Biosite Incorporated | Diagnostic markers of acute coronary syndromes and methods of use thereof |
WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
US20030119209A1 (en) * | 2001-12-21 | 2003-06-26 | Kaylor Rosann Marie | Diagnostic methods and devices |
US6986995B2 (en) * | 2002-02-28 | 2006-01-17 | Prometheus Laboratories, Inc. | Methods of diagnosing liver fibrosis |
US6847451B2 (en) * | 2002-05-01 | 2005-01-25 | Lifescan, Inc. | Apparatuses and methods for analyte concentration determination |
GB0215509D0 (en) * | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
US7056702B2 (en) * | 2002-12-16 | 2006-06-06 | Kimberly Clark Co | Detecting lipocalin |
DK1616184T4 (da) * | 2003-03-27 | 2018-08-13 | Childrens Hospital Med Ct | Fremgangsmåde og kit til at påvise tidlig begyndelse af renal tubulær cellebeskadigelse |
EP2661963B1 (en) * | 2004-05-06 | 2015-09-16 | The Trustees of Columbia University in the City of New York | Method for diagnosing acute renal failure or chronic renal failure |
US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
AU2007217861A1 (en) * | 2006-02-17 | 2007-08-30 | Children's Medical Center Corporation | Free NGAL as a biomarker for cancer |
US20080061149A1 (en) * | 2006-09-11 | 2008-03-13 | Colin Tanner | Proximity payment card with security interlock |
US20090124022A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
US20090123970A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
DE102008025144A1 (de) * | 2008-05-26 | 2009-12-03 | Siemens Aktiengesellschaft | Anordnung zur Erhöhung der Lese- und Schreibsicherheit von RFID-Labeln |
-
2005
- 2005-12-20 DK DK09154624.2T patent/DK2128625T3/da active
- 2005-12-20 ES ES17152153T patent/ES2703434T3/es active Active
- 2005-12-20 AU AU2005318689A patent/AU2005318689B2/en not_active Ceased
- 2005-12-20 SI SI200530897T patent/SI1831699T1/sl unknown
- 2005-12-20 ES ES05820913T patent/ES2336345T3/es active Active
- 2005-12-20 NZ NZ555926A patent/NZ555926A/en not_active IP Right Cessation
- 2005-12-20 KR KR1020077016768A patent/KR100971305B1/ko active IP Right Review Request
- 2005-12-20 ES ES09154624.2T patent/ES2622467T3/es active Active
- 2005-12-20 EP EP05820913A patent/EP1831699B1/en not_active Revoked
- 2005-12-20 CA CA2591113A patent/CA2591113C/en active Active
- 2005-12-20 PL PL18195687T patent/PL3489689T3/pl unknown
- 2005-12-20 WO PCT/DK2005/000806 patent/WO2006066587A1/en active Application Filing
- 2005-12-20 CN CN2005800481759A patent/CN101163971B/zh active Active
- 2005-12-20 US US11/722,025 patent/US20090170143A1/en not_active Abandoned
- 2005-12-20 EP EP17152153.7A patent/EP3208616B1/en active Active
- 2005-12-20 EP EP18195687.1A patent/EP3489689B1/en active Active
- 2005-12-20 JP JP2007547181A patent/JP4741603B2/ja active Active
- 2005-12-20 AT AT05820913T patent/ATE448484T1/de active
- 2005-12-20 PL PL05820913T patent/PL1831699T3/pl unknown
- 2005-12-20 ES ES18195687T patent/ES2818028T3/es active Active
- 2005-12-20 DK DK05820913.1T patent/DK1831699T3/da active
- 2005-12-20 DK DK18195687.1T patent/DK3489689T3/da active
- 2005-12-20 EP EP09154624.2A patent/EP2128625B1/en active Active
- 2005-12-20 DE DE602005013288T patent/DE602005013288D1/de active Active
-
2007
- 2007-06-12 IL IL183872A patent/IL183872A/en not_active IP Right Cessation
- 2007-07-13 ZA ZA2007/05776A patent/ZA200705776B/en unknown
- 2007-12-18 HK HK07113788.2A patent/HK1105454A1/xx unknown
-
2015
- 2015-01-08 US US14/592,016 patent/US20150132772A1/en not_active Abandoned
- 2015-09-16 US US14/855,587 patent/US20160003851A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2128625T3 (da) | Bestemmelse af neutrofil gelatinase-associeret lipocalin (NGAL) som diagnostisk markør for nyrelidelser | |
US20190170770A1 (en) | Diagnostic Test to Exclude Significant Renal Injury | |
EP2137538B1 (en) | Diagnostic test for renal injury | |
Class et al. | Patent application title: DIAGNOSTIC TEST TO EXCLUDE SIGNIFICANT RENAL INJURY Inventors: Lars Otto Uttenthal (Salamanca, ES) Antibodyshop A/s (Gentofte, DE) Kristian Bangert (Holte, DE) Assignees: AntibodyShop A/S | |
WO2022192751A2 (en) | Urine test predicts kidney injury and death in covid-19 | |
KR101363575B1 (ko) | 신부전증에 대한 신규 바이오마커 및 그의 용도 |